Aurinia Pharmaceuticals: There's Still Time For Sales Growth

Aurinia Pharmaceuticals Inc.'s (NASDAQ: AUPH ) sole approved product, Lupkynis, for the treatment of lupus nephritis, didn't produce strong product revenue growth going from Q2'24 to Q3'24. The stock is now approaching Q4'24 earnings and a resumption of sales growth could again produce a rallyScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but ...